2022-06-300001648257--12-312022Q2false00016482572022-01-012022-06-300001648257us-gaap:CommonStockMember2022-01-012022-06-300001648257us-gaap:RetainedEarningsMember2022-06-300001648257us-gaap:ParentMember2022-06-300001648257us-gaap:NoncontrollingInterestMember2022-06-300001648257us-gaap:AdditionalPaidInCapitalMember2022-06-300001648257us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001648257us-gaap:RetainedEarningsMember2021-12-310001648257us-gaap:ParentMember2021-12-310001648257us-gaap:NoncontrollingInterestMember2021-12-310001648257us-gaap:AdditionalPaidInCapitalMember2021-12-310001648257us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001648257us-gaap:RetainedEarningsMember2021-06-300001648257us-gaap:ParentMember2021-06-300001648257us-gaap:NoncontrollingInterestMember2021-06-300001648257us-gaap:AdditionalPaidInCapitalMember2021-06-300001648257us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001648257us-gaap:RetainedEarningsMember2020-12-310001648257us-gaap:ParentMember2020-12-310001648257us-gaap:NoncontrollingInterestMember2020-12-310001648257us-gaap:AdditionalPaidInCapitalMember2020-12-310001648257us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001648257hcm:HCMLShareOptionSchemeMember2020-12-310001648257hcm:ExecutiveDirectorMemberhcm:HCMLShareOptionSchemeMemberdei:AdrMember2022-05-012022-05-310001648257hcm:ShareOptionScheme2005Member2022-06-300001648257hcm:HCMLShareOptionSchemeMember2021-01-012021-12-310001648257hcm:HCMLShareOptionSchemeMember2020-01-012020-12-310001648257hcm:HCMLShareOptionSchemeMember2021-12-310001648257srt:MinimumMemberhcm:HCMLShareOptionSchemeMember2022-01-012022-06-300001648257srt:MaximumMemberhcm:HCMLShareOptionSchemeMember2022-01-012022-06-300001648257hcm:ShareOptionScheme2005Member2005-06-042005-06-040001648257hcm:OrdinarySharesOrAmericanDepositaryShareMemberhcm:LongTermIncentivePlanMember2022-06-300001648257hcm:OrdinarySharesOrAmericanDepositaryShareMemberhcm:LongTermIncentivePlanMember2021-12-310001648257hcm:OrdinarySharesOrAmericanDepositaryShareMemberhcm:LongTermIncentivePlanMember2020-12-310001648257hcm:ExecutiveDirectorMemberhcm:HCMLShareOptionSchemeMember2022-05-012022-05-310001648257hcm:AwardsVestingInFourYearsMemberhcm:HCMLShareOptionSchemeMember2022-01-012022-06-300001648257us-gaap:OtherNoncurrentLiabilitiesMember2022-06-300001648257hcm:OtherPayablesAccrualsAndAdvanceReceiptsMember2022-06-300001648257us-gaap:OtherNoncurrentLiabilitiesMember2021-12-310001648257hcm:OtherPayablesAccrualsAndAdvanceReceiptsMember2021-12-310001648257hcm:ThirdPartiesMemberhcm:OtherCollaborationRoyaltiesRevenueMember2022-01-012022-06-300001648257hcm:ThirdPartiesMemberhcm:OtherCollaborationLicensingRevenueMember2022-01-012022-06-300001648257hcm:ThirdPartiesMemberhcm:CollaborationResearchAndDevelopmentMember2022-01-012022-06-300001648257hcm:RelatedPartiesMemberhcm:ResearchAndDevelopmentServicesMember2022-01-012022-06-300001648257hcm:ThirdPartiesMemberhcm:OtherCollaborationRoyaltiesRevenueMember2021-01-012021-06-300001648257hcm:ThirdPartiesMemberhcm:CollaborationResearchAndDevelopmentMember2021-01-012021-06-300001648257hcm:RelatedPartiesMemberhcm:ResearchAndDevelopmentServicesMember2021-01-012021-06-300001648257hcm:RelatedPartyTransactionSalesOfGoodsMemberus-gaap:SubsidiaryOfCommonParentMember2022-01-012022-06-300001648257hcm:RelatedPartyTransactionResearchAndDevelopmentServicesMemberus-gaap:EquityMethodInvesteeMember2022-01-012022-06-300001648257hcm:RelatedPartyTransactionSalesOfGoodsMemberus-gaap:SubsidiaryOfCommonParentMember2021-01-012021-06-300001648257hcm:RelatedPartyTransactionResearchAndDevelopmentServicesMemberus-gaap:EquityMethodInvesteeMember2021-01-012021-06-300001648257hcm:CustomerTwoMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberhcm:OncologyOrImmunologySegmentMember2022-01-012022-06-300001648257hcm:CustomerOneMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberhcm:OncologyOrImmunologySegmentMember2022-01-012022-06-300001648257us-gaap:IntersegmentEliminationMemberhcm:OncologyOrImmunologySegmentMember2022-01-012022-06-300001648257hcm:ThirdPartiesMemberhcm:OtherVenturesSegmentMember2022-01-012022-06-300001648257hcm:ThirdPartiesMemberhcm:OncologyOrImmunologySegmentMember2022-01-012022-06-300001648257hcm:ResearchAndDevelopmentServicesMemberhcm:OncologyOrImmunologySegmentMember2022-01-012022-06-300001648257hcm:RelatedPartiesMemberhcm:OtherVenturesSegmentMember2022-01-012022-06-300001648257hcm:RelatedPartiesMemberhcm:OncologyOrImmunologySegmentMember2022-01-012022-06-300001648257hcm:OtherCollaborationRoyaltiesRevenueMemberhcm:OncologyOrImmunologySegmentMember2022-01-012022-06-300001648257hcm:OtherCollaborationLicensingRevenueMemberhcm:OncologyOrImmunologySegmentMember2022-01-012022-06-300001648257hcm:MarketedProductsMemberhcm:OncologyOrImmunologySegmentMember2022-01-012022-06-300001648257hcm:GoodsDistributionAndOtherProductsMemberhcm:OtherVenturesSegmentMember2022-01-012022-06-300001648257hcm:CommercializationServicesMemberhcm:OncologyOrImmunologySegmentMember2022-01-012022-06-300001648257hcm:CollaborationResearchAndDevelopmentMemberhcm:OncologyOrImmunologySegmentMember2022-01-012022-06-300001648257hcm:ThirdPartiesMember2022-01-012022-06-300001648257hcm:ResearchAndDevelopmentServicesMember2022-01-012022-06-300001648257hcm:RelatedPartiesMember2022-01-012022-06-300001648257hcm:OtherVenturesSegmentMember2022-01-012022-06-300001648257hcm:OtherCollaborationRoyaltiesRevenueMember2022-01-012022-06-300001648257hcm:OtherCollaborationLicensingRevenueMember2022-01-012022-06-300001648257hcm:OncologyOrImmunologySegmentMember2022-01-012022-06-300001648257hcm:MarketedProductsMember2022-01-012022-06-300001648257hcm:GoodsDistributionAndOtherProductsMember2022-01-012022-06-300001648257hcm:CommercializationServicesMember2022-01-012022-06-300001648257hcm:CollaborationResearchAndDevelopmentMember2022-01-012022-06-300001648257hcm:CustomerThreeMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberhcm:OtherVenturesSegmentMember2021-01-012021-06-300001648257hcm:CustomerOneMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberhcm:OncologyOrImmunologySegmentMember2021-01-012021-06-300001648257us-gaap:IntersegmentEliminationMemberhcm:OncologyOrImmunologySegmentMember2021-01-012021-06-300001648257hcm:ThirdPartiesMemberhcm:OtherVenturesSegmentMember2021-01-012021-06-300001648257hcm:ThirdPartiesMemberhcm:OncologyOrImmunologySegmentMember2021-01-012021-06-300001648257hcm:ResearchAndDevelopmentServicesMemberhcm:OncologyOrImmunologySegmentMember2021-01-012021-06-300001648257hcm:RelatedPartiesMemberhcm:OtherVenturesSegmentMember2021-01-012021-06-300001648257hcm:RelatedPartiesMemberhcm:OncologyOrImmunologySegmentMember2021-01-012021-06-300001648257hcm:OtherCollaborationRoyaltiesRevenueMemberhcm:OncologyOrImmunologySegmentMember2021-01-012021-06-300001648257hcm:MarketedProductsMemberhcm:OncologyOrImmunologySegmentMember2021-01-012021-06-300001648257hcm:GoodsDistributionAndOtherProductsMemberhcm:OtherVenturesSegmentMember2021-01-012021-06-300001648257hcm:CommercializationServicesMemberhcm:OncologyOrImmunologySegmentMember2021-01-012021-06-300001648257hcm:CollaborationResearchAndDevelopmentMemberhcm:OncologyOrImmunologySegmentMember2021-01-012021-06-300001648257hcm:ThirdPartiesMember2021-01-012021-06-300001648257hcm:ResearchAndDevelopmentServicesMember2021-01-012021-06-300001648257hcm:RelatedPartiesMember2021-01-012021-06-300001648257hcm:OtherVenturesSegmentMember2021-01-012021-06-300001648257hcm:OtherCollaborationRoyaltiesRevenueMember2021-01-012021-06-300001648257hcm:OncologyOrImmunologySegmentMember2021-01-012021-06-300001648257hcm:MarketedProductsMember2021-01-012021-06-300001648257hcm:GoodsDistributionAndOtherProductsMember2021-01-012021-06-300001648257hcm:CommercializationServicesMember2021-01-012021-06-300001648257hcm:CollaborationResearchAndDevelopmentMember2021-01-012021-06-300001648257hcm:CollaborativeArrangementsMember2022-01-012022-06-300001648257hcm:CollaborativeArrangementsMember2021-01-012021-06-300001648257us-gaap:EquityMethodInvesteeMember2022-01-012022-06-300001648257us-gaap:EquityMethodInvesteeMember2021-01-012021-06-300001648257hcm:RelatedPartyTransactionMarketingServicesMemberus-gaap:SubsidiaryOfCommonParentMember2022-01-012022-06-300001648257hcm:RelatedPartyTransactionMarketingServicesMemberus-gaap:EquityMethodInvesteeMember2022-01-012022-06-300001648257hcm:RelatedPartyTransactionManagementServiceMemberus-gaap:SubsidiaryOfCommonParentMember2022-01-012022-06-300001648257hcm:RelatedPartyTransactionMarketingServicesMemberus-gaap:SubsidiaryOfCommonParentMember2021-01-012021-06-300001648257hcm:RelatedPartyTransactionManagementServiceMemberus-gaap:SubsidiaryOfCommonParentMember2021-01-012021-06-300001648257us-gaap:RetainedEarningsMember2022-01-012022-06-300001648257hcm:AllOtherEquityMethodInvesteesMember2022-01-012022-06-300001648257hcm:AllOtherEquityMethodInvesteesMember2021-01-012021-06-300001648257us-gaap:CommonStockMemberhcm:FurtherPublicOfferingMember2021-07-152021-07-150001648257us-gaap:CommonStockMemberhcm:FurtherPublicOfferingMember2021-06-302021-06-300001648257us-gaap:CommonStockMember2021-04-142021-04-140001648257us-gaap:UnsecuredDebtMemberus-gaap:NotesPayableToBanksMember2019-05-012019-05-310001648257us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-06-300001648257us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMemberus-gaap:CapitalAdditionsMember2022-01-012022-06-300001648257us-gaap:CapitalAdditionsMember2022-01-012022-06-300001648257us-gaap:RevolvingCreditFacilityMember2022-05-310001648257us-gaap:SecuredDebtMemberhcm:FixedAssetLoanFacilityMember2021-10-310001648257us-gaap:RevolvingCreditFacilityMember2020-08-310001648257us-gaap:UnsecuredDebtMemberus-gaap:RevolvingCreditFacilityMember2019-05-310001648257us-gaap:UnsecuredDebtMemberus-gaap:NotesPayableToBanksMember2019-05-310001648257us-gaap:UnsecuredDebtMember2019-05-310001648257us-gaap:SecuredDebtMemberhcm:FixedAssetLoanFacilityMember2022-06-300001648257us-gaap:RevolvingCreditFacilityMember2022-06-300001648257us-gaap:SecuredDebtMemberhcm:FixedAssetLoanFacilityMember2021-12-310001648257us-gaap:RevolvingCreditFacilityMember2021-12-310001648257hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember2021-01-012021-06-300001648257hcm:AllOtherEquityMethodInvesteesMember2022-06-300001648257hcm:AllOtherEquityMethodInvesteesMember2021-12-310001648257hcm:HCMLShareOptionSchemeMember2022-06-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2022-01-012022-06-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2021-01-012021-06-300001648257hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember2021-01-012021-06-300001648257hcm:LongTermIncentivePlanMember2022-06-300001648257hcm:LongTermIncentivePlanMember2021-12-310001648257us-gaap:RevolvingCreditFacilityMember2022-05-012022-05-310001648257us-gaap:SecuredDebtMemberhcm:FixedAssetLoanFacilityMember2021-10-012021-10-310001648257us-gaap:RevolvingCreditFacilityMember2020-08-012020-08-310001648257us-gaap:UnsecuredDebtMember2019-05-012019-05-310001648257us-gaap:RevolvingCreditFacilityMemberhcm:HongKongInterbankOfferedRateMember2022-05-012022-05-310001648257us-gaap:SecuredDebtMemberhcm:FixedAssetLoanFacilityMemberus-gaap:PrimeRateMember2021-10-012021-10-310001648257us-gaap:RevolvingCreditFacilityMemberhcm:HongKongInterbankOfferedRateMember2020-08-012020-08-310001648257us-gaap:UnsecuredDebtMemberhcm:HongKongInterbankOfferedRateMember2019-05-012019-05-310001648257hcm:UnitedStatesAndOthersMember2022-01-012022-06-300001648257country:HK2022-01-012022-06-300001648257country:CN2022-01-012022-06-300001648257hcm:UnitedStatesAndOthersMember2021-01-012021-06-300001648257country:HK2021-01-012021-06-300001648257country:CN2021-01-012021-06-300001648257hcm:ThirdPartiesMemberus-gaap:ProductMember2022-01-012022-06-300001648257hcm:ThirdPartiesMemberhcm:CommercializationServicesMember2022-01-012022-06-300001648257hcm:RelatedPartiesMemberus-gaap:ProductMember2022-01-012022-06-300001648257hcm:NonControllingShareholdersOfSubsidiariesMember2022-01-012022-06-300001648257hcm:ThirdPartiesMemberus-gaap:ProductMember2021-01-012021-06-300001648257hcm:ThirdPartiesMemberhcm:CommercializationServicesMember2021-01-012021-06-300001648257hcm:RelatedPartiesMemberus-gaap:ProductMember2021-01-012021-06-300001648257us-gaap:CommonStockMember2022-06-300001648257us-gaap:CommonStockMember2021-12-310001648257us-gaap:CommonStockMember2021-06-300001648257us-gaap:CommonStockMember2020-12-310001648257currency:USD2022-06-300001648257currency:HKD2022-06-300001648257currency:GBP2022-06-300001648257currency:EUR2022-06-300001648257currency:CNY2022-06-300001648257currency:USD2021-12-310001648257currency:HKD2021-12-310001648257currency:GBP2021-12-310001648257currency:EUR2021-12-310001648257currency:CNY2021-12-310001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2022-06-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2021-12-310001648257us-gaap:OperatingSegmentsMemberhcm:UnitedStatesAndOthersMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2022-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:MarketedProductsSubsegmentMember2022-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OtherVenturesSegmentMember2022-06-300001648257hcm:CorporateAndReconcilingItemsMember2022-06-300001648257us-gaap:OperatingSegmentsMemberhcm:UnitedStatesAndOthersMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2021-12-310001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:MarketedProductsSubsegmentMember2021-12-310001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OtherVenturesSegmentMember2021-12-310001648257hcm:CorporateAndReconcilingItemsMember2021-12-3100016482572021-06-3000016482572020-12-310001648257us-gaap:SellingGeneralAndAdministrativeExpensesMemberhcm:LongTermIncentivePlanMember2022-01-012022-06-300001648257us-gaap:SellingGeneralAndAdministrativeExpensesMemberhcm:HCMLShareOptionSchemeMember2022-01-012022-06-300001648257us-gaap:ResearchAndDevelopmentExpenseMemberhcm:LongTermIncentivePlanMember2022-01-012022-06-300001648257us-gaap:ResearchAndDevelopmentExpenseMemberhcm:HCMLShareOptionSchemeMember2022-01-012022-06-300001648257us-gaap:LiabilityMemberhcm:LongTermIncentivePlanMember2022-01-012022-06-300001648257us-gaap:CostOfSalesMemberhcm:LongTermIncentivePlanMember2022-01-012022-06-300001648257us-gaap:CostOfSalesMemberhcm:HCMLShareOptionSchemeMember2022-01-012022-06-300001648257us-gaap:AdditionalPaidInCapitalMemberhcm:LongTermIncentivePlanMember2022-01-012022-06-300001648257us-gaap:SellingGeneralAndAdministrativeExpensesMemberhcm:LongTermIncentivePlanMember2021-01-012021-06-300001648257us-gaap:SellingGeneralAndAdministrativeExpensesMemberhcm:HCMLShareOptionSchemeMember2021-01-012021-06-300001648257us-gaap:ResearchAndDevelopmentExpenseMemberhcm:LongTermIncentivePlanMember2021-01-012021-06-300001648257us-gaap:ResearchAndDevelopmentExpenseMemberhcm:HCMLShareOptionSchemeMember2021-01-012021-06-300001648257us-gaap:LiabilityMemberhcm:LongTermIncentivePlanMember2021-01-012021-06-300001648257us-gaap:CostOfSalesMemberhcm:LongTermIncentivePlanMember2021-01-012021-06-300001648257us-gaap:CostOfSalesMemberhcm:HCMLShareOptionSchemeMember2021-01-012021-06-300001648257us-gaap:AdditionalPaidInCapitalMemberhcm:LongTermIncentivePlanMember2021-01-012021-06-300001648257hcm:HCMLShareOptionSchemeMember2021-01-012021-06-300001648257us-gaap:NoncontrollingInterestMember2022-01-012022-06-300001648257us-gaap:NoncontrollingInterestMember2021-01-012021-06-300001648257hcm:ThirdPartiesMember2022-06-300001648257hcm:NotLaterThanThreeMonthsMember2022-06-300001648257hcm:NonControllingShareholdersOfSubsidiariesMember2022-06-300001648257hcm:LaterThanOneYearMember2022-06-300001648257hcm:BetweenThreeMonthsToSixMonthsMember2022-06-300001648257hcm:BetweenSixMonthsToOneYearMember2022-06-300001648257hcm:ThirdPartiesMember2021-12-310001648257hcm:NotLaterThanThreeMonthsMember2021-12-310001648257hcm:NonControllingShareholdersOfSubsidiariesMember2021-12-310001648257hcm:LaterThanOneYearMember2021-12-310001648257hcm:BetweenThreeMonthsToSixMonthsMember2021-12-310001648257hcm:BetweenSixMonthsToOneYearMember2021-12-310001648257hcm:EpizymeIncMember2021-08-072021-08-070001648257hcm:EpizymeIncMember2021-08-0700016482572021-08-070001648257us-gaap:ParentMember2022-01-012022-06-300001648257us-gaap:AdditionalPaidInCapitalMember2022-01-012022-06-300001648257us-gaap:RetainedEarningsMember2021-01-012021-06-300001648257srt:MinimumMember2022-01-012022-06-300001648257srt:MaximumMember2022-01-012022-06-300001648257srt:MinimumMember2021-01-012021-12-310001648257srt:MaximumMember2021-01-012021-12-310001648257hcm:SalesMilestonesMember2021-08-070001648257hcm:DevelopmentAndRegulatoryMilestonesMember2021-08-070001648257us-gaap:ParentMember2021-01-012021-06-300001648257us-gaap:AdditionalPaidInCapitalMember2021-01-012021-06-300001648257us-gaap:CommonStockMember2021-01-012021-06-300001648257hcm:LongTermIncentivePlanMember2021-01-012021-06-300001648257hcm:VestingBasedOnPerformanceMemberhcm:GrantDateDecember142021OneMemberhcm:LongTermIncentivePlanMember2021-12-142021-12-140001648257hcm:VestingBasedOnPerformanceMemberhcm:LongTermIncentivePlanMember2021-10-202021-10-200001648257hcm:AwardsVestingInFourYearsMemberhcm:HCMLShareOptionSchemeMember2022-06-300001648257hcm:HCMLShareOptionSchemeMember2022-01-012022-06-300001648257hcm:VestingBasedOnPerformanceMemberhcm:LongTermIncentivePlanMember2022-05-232022-05-230001648257hcm:VestingBasedOnPerformanceMemberhcm:LongTermIncentivePlanMember2021-09-012021-09-010001648257hcm:VestingBasedOnPerformanceMemberhcm:LongTermIncentivePlanMember2021-03-262021-03-260001648257hcm:VestingBasedOnPerformanceMemberhcm:GrantDateMay232022Memberhcm:LongTermIncentivePlanMember2022-05-230001648257hcm:VestingBasedOnPerformanceMemberhcm:GrantDateDecember142021TwoMemberhcm:LongTermIncentivePlanMember2021-12-140001648257hcm:VestingBasedOnPerformanceMemberhcm:GrantDateDecember142021OneMemberhcm:LongTermIncentivePlanMember2021-12-140001648257hcm:VestingBasedOnPerformanceMemberhcm:GrantDateOctober202021Memberhcm:LongTermIncentivePlanMember2021-10-200001648257hcm:VestingBasedOnPerformanceMemberhcm:GrantDateSeptember12021TwoMemberhcm:LongTermIncentivePlanMember2021-09-010001648257hcm:VestingBasedOnPerformanceMemberhcm:GrantDateSeptember12021OneMemberhcm:LongTermIncentivePlanMember2021-09-010001648257hcm:VestingBasedOnPerformanceMemberhcm:GrantDateMarch2021Memberhcm:LongTermIncentivePlanMember2021-03-260001648257hcm:OrdinarySharesOrAmericanDepositaryShareMemberhcm:LongTermIncentivePlanMember2021-01-012021-12-310001648257hcm:OrdinarySharesOrAmericanDepositaryShareMemberhcm:LongTermIncentivePlanMember2022-01-012022-06-300001648257hcm:OrdinarySharesOrAmericanDepositaryShareMemberhcm:LongTermIncentivePlanMember2021-01-012021-06-300001648257hcm:LongTermIncentivePlanMember2022-01-012022-06-3000016482572021-01-012021-12-310001648257us-gaap:SubsidiaryOfCommonParentMember2022-01-012022-06-300001648257us-gaap:SubsidiaryOfCommonParentMember2021-01-012021-12-310001648257us-gaap:SubsidiaryOfCommonParentMember2022-06-300001648257us-gaap:EquityMethodInvesteeMember2022-06-300001648257us-gaap:SubsidiaryOfCommonParentMember2021-12-310001648257us-gaap:EquityMethodInvesteeMember2021-12-310001648257us-gaap:OperatingSegmentsMemberhcm:UnitedStatesAndOthersMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2022-01-012022-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2022-01-012022-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:MarketedProductsSubsegmentMember2022-01-012022-06-300001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2022-01-012022-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OtherVenturesSegmentMember2022-01-012022-06-300001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMember2022-01-012022-06-300001648257hcm:CorporateAndReconcilingItemsMember2022-01-012022-06-300001648257us-gaap:OperatingSegmentsMemberhcm:UnitedStatesAndOthersMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2021-01-012021-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2021-01-012021-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:MarketedProductsSubsegmentMember2021-01-012021-06-300001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2021-01-012021-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OtherVenturesSegmentMember2021-01-012021-06-300001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMember2021-01-012021-06-300001648257hcm:CorporateAndReconcilingItemsMember2021-01-012021-06-300001648257us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-06-300001648257us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-06-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2022-06-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2021-12-310001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2021-06-300001648257hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember2021-06-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2020-12-310001648257hcm:HutchisonWhampoaGuangzhouBaiyunshanChineseMedicineCompanyLimitedMember2020-12-3100016482572022-06-2700016482572021-10-212021-12-310001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2022-06-300001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2022-06-300001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMember2022-06-300001648257us-gaap:OperatingSegmentsMembercountry:CNhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2021-12-310001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMemberhcm:ResearchAndDevelopmentSubsegmentMember2021-12-310001648257us-gaap:OperatingSegmentsMemberhcm:OncologyOrImmunologySegmentMember2021-12-310001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2022-01-012022-06-300001648257hcm:ShanghaiHutchisonPharmaceuticalsLimitedMember2021-01-012021-06-300001648257hcm:NonControllingShareholdersOfSubsidiariesMember2021-01-012021-06-3000016482572021-01-012021-06-300001648257hcm:SeroquelMember2022-06-3000016482572022-06-3000016482572021-12-31hcm:claimiso4217:USDxbrli:pureiso4217:CNYhcm:areahcm:customerhcm:Votexbrli:sharesiso4217:USDxbrli:sharesiso4217:HKD

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of August 2022

Commission File Number: 001-37710

HUTCHMED (CHINA) LIMITED

(Translation of registrant’s name into English)

48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

HUTCHMED (CHINA) LIMITED

Form 6-K

EXHIBIT INDEX

Exhibit No.

    

Description

Exhibit 99.1

Announcement relating to unaudited financial results as of and for the six months ended June 30, 2022

Exhibit 99.2

HUTCHMED (China) Limited supplemental disclosures

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

HUTCHMED (CHINA) LIMITED

By:

/s/ JOHNNY CHENG

Name:

Johnny Cheng

Title:

Chief Financial Officer

Date: August 1, 2022